VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis
Blythe C. Dillingham(Children's National), Jesse M. Damsker(ReveraGen BioPharma (United States)), Erica Reeves(ReveraGen BioPharma (United States)), Amanda M. Mullen(Children's National), Susan M. Knoblach(Children's National), Luca Bello(Children's National), Gina M. Many(Pacific Northwest National Laboratory), Eric P. Hoffman(Binghamton University), Brennan Harmon(Children's National), Edward M. Connor(ReveraGen BioPharma (United States)), Christopher R. Heier(Children's National), John M. McCall(ReveraGen BioPharma (United States)), Kanneboyina Nagaraju(Binghamton University)
Cited by 26
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Expression Profiling in the Muscular Dystrophies
|The Journal of Cell Biology|2000|481
Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies.
|PubMed|1991|401
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
|The Journal of Experimental Medicine|2005|395